{
  "docId": "019de073-8568-725b-9a17-a64262808fc8",
  "docSlug": "d872feff7a8967ecac479e446ba0e3da",
  "documentTitle": "Context Therapeutics | Investor Presentation Deck | 25 slides",
  "authorId": "context-therapeutics",
  "authorName": "Context Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 25,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8568-725b-9a17-a64262808fc8/24",
  "deckHref": "/decks/019de073-8568-725b-9a17-a64262808fc8",
  "deckJsonHref": "/decks/019de073-8568-725b-9a17-a64262808fc8.json",
  "deckAnchorHref": "/decks/019de073-8568-725b-9a17-a64262808fc8#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.88,
        "x": 0.06,
        "y": 0.28
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79f5a83e-0f0d-4590-b551-46a483ceed2e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.14,
        "x": 0.245,
        "y": 0.595
      },
      "kind": "list",
      "text": "High-Value Targets: Progesterone Receptor and Claudin 6",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "710c1da0-280d-4335-a73b-6c97aa971adc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.13,
        "x": 0.435,
        "y": 0.595
      },
      "kind": "list",
      "text": "Near-Term Milestones: Multiple Data Readouts in Q4 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "823fc3e3-d406-4c32-be83-bf7fffeeee9c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.13,
        "x": 0.81,
        "y": 0.595
      },
      "kind": "list",
      "text": "Financial Strength: Expected Cash Runway into Q1 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c2dd290-7be9-4859-ac96-377f258441b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.14,
        "x": 0.62,
        "y": 0.595
      },
      "kind": "list",
      "text": "Strong Team: Deep Domain Experience, Track Record of Success",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c840c3b0-0757-40f8-b5a6-2327ae48dc1b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.12,
        "x": 0.075,
        "y": 0.595
      },
      "kind": "list",
      "text": "Large Unmet Need: Female Cancers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0caf3c7-70e2-4b46-9460-c77cde059a99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.273,
        "x": 0.048,
        "y": 0.075
      },
      "kind": "title",
      "text": "Investment Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc551ce5-d632-4817-938c-e8e5114685fa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 24,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6f563f0a-bba6-40be-8cea-242e5c29e44d",
      "evidence": "Slides 11-24 outline the potential of ONA-XR and CLDN6xCD3 Bispecific Antibody Program",
      "position": 0,
      "objective": "Highlight the benefits of investment in Context Therapeutics",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}